On Jan. 29, 2021, Humanigen announced it had completed enrollment for its pivotal phase 3 study of lenzilumab for COVID-19. The Company expects to announce top-line data in March 2021.

The primary objective of this Phase 3 randomized, double-blind, placebo-controlled clinical trial, which enrolled 520 patients, was to determine whether lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome and improve ventilator-free survival in hospitalized and hypoxic patients with COVID-19 pneumonia.